Neurocrine Biosciences, Inc. (NBIX) Q4 2009 Earnings Results

Neurocrine Biosciences Beats on EPS, Stock Down 0.43%

Neurocrine Biosciences reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock fell slightly by 0.43%, indicating that the market may have been looking for more clarity or additional positive news. The lack of revenue data and guidance could have contributed to the stock's downward movement.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.20	N/A	+29.58%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the EPS beat, highlighting ongoing efforts in their pipeline. However, they did not provide specific guidance for the future.

We are pleased with our EPS performance despite the challenges.

Our focus remains on advancing our pipeline and strategic initiatives.

Neurocrine Biosciences Beats on EPS, Stock Down 0.43%

Key numbers

Management commentary

Neurocrine Biosciences, Inc.

More earnings this week

Neurocrine Biosciences Beats on EPS, Stock Down 0.43%

Key numbers

Management commentary